Clinical Trials Logo

Clinical Trial Summary

Background:About 50% of subclinical heart failure (Sub-HF) patients might have residual lung ultrasound B-lines (LU-BL). Sub-HF is insensitive to widely used imaging examinations, like x-ray or echocardiography, but lung ultrasound (LU) can sufficiently detect pulmonary congestion in Sub-HF patients. In this trial, we sought to evaluate the impact of residual B-lines at discharge and other clinical findings of heart failure (HF) patients on rehospitalization due to HF and all-cause mortality (composite primary outcome) up to 1 year post discharge. The impact of intensive HF therapy post discharge on outcome up to 1 year after discharge will also be investigated. Aim: IMP-OUTCOME is a prospective, single-center, observational cohort study, which is designed to investigate whether residual LU-BL at discharge are the determinants of poor outcome in Sub-HF patients and if intensive HF therapy post discharge might improve the outcome of sub-HF patients with residual B-lines up to 1 year after discharge. Methods and results: After receiving the standardized treatment of HF according to current guidelines, 233 HF patients with improved signs and symptoms of HF would be grouped into < 3 B-lines and ≥ 3 B-lines groups according to LU-BL measurement within 48 hours before discharge, and the group with ≥ 3 B-lines will be further divided into the conventional therapy group and the intensive therapy group at 1:1 ratio. Intensive therapy group will be treated with SGLT2 inhibitor beyond other medications and regularly monitored by HF nurses and cardiologists at 1 month interval. Patient-relates basic, clinical data including sex, age, blood chemistry, imaging examination, drug utilization, and so on will be obtained and analyzed. Following discharge from the hospital, patients will be followed up at 1 month, 3 months, 6 months, and 1 year by clinical visit or telephone call. The primary endpoint is the composite of re-hospitalization for worsening HF and all-cause death during follow-up. Secondary endpoints include the change in the Duke Activity Status Index (DASI) and NT-pro BNP and 6-min walk distance change. Up to the end of 2022, approximately 233 HF patients will be enrolled. Follow up is expected to be completed around the end of 2023, and primary results will be available by early 2024. Conclusion: This trial will clarify the impact of residual B-lines on outcome of discharged HF patients and the impact of intensive HF management in discharged patients with residual B-lines up to 1 year after discharge.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05035459
Study type Observational
Source Xiangtan Central Hospital
Contact Jianping Zeng
Phone +86 15292271982
Email [email protected]
Status Not yet recruiting
Start date September 1, 2021
Completion date January 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04475315 - Ventricular Sling for Heart Failure With Reduced Ejection Fraction N/A
Not yet recruiting NCT05034354 - Virtual Remote Physiological Monitoring Program of Children With Heart Disease N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT04549181 - Problem-Solving for Rural Heart Failure Dyads N/A
Completed NCT02748876 - Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy N/A
Recruiting NCT03300791 - Predictive Models of Readmission in Heart Failure
Completed NCT03294512 - Pilot and Feasibility Study of a MAWDS (Medications, Activity, Weight, Diet and Symptoms) Heart Failure Mobile Platform N/A
Terminated NCT03565328 - The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects Phase 2
Terminated NCT04066738 - Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy N/A
Recruiting NCT04573166 - Personalized Atrial Septostomy for Heart Failure N/A
Recruiting NCT04537104 - Remote Monitoring in Patients With Heart Failure
Active, not recruiting NCT03560167 - Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation N/A
Not yet recruiting NCT03928639 - Structural Heart and Valve Network PROSPECTIVE Registry
Active, not recruiting NCT04736433 - Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.
Terminated NCT03281122 - A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction Phase 1
Enrolling by invitation NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A